Nanoparticles are becoming an attractive option for targeted cancer therapy, but do these new delivery methods interfere with their cargo's functions? The Hemann Lab teamed up with the MIT Department of Chemistry’s Johnson Lab to measure cell response to their previously developed high capacity nanoparticles. The cells responded as expected to both doxorubicin and camptothecin; however, the DNA damage induced by cisplatin more closely resembled that of oxaliplatin (another chemotherapy drug.) The Johnson Lab is now working on an improved design for cisplatin delivery that retains the original mechanism of the drug. Read more.